Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Heptares Adds Two GPCR Partners
by Lisa M. Jarvis
December 7, 2015
| A version of this story appeared in
Volume 93, Issue 48
Heptares Therapeutics has struck deals with two companies hoping to tap into its G protein-coupled receptor (GPCR) expertise. Heptares and Pfizer will work together to develop drugs targeting up to 10 GPCRs, with the biotech earning up to $189 million per target. Pfizer will also take a stake worth $33 million in Heptares’s parent company, Sosei. Separately, Teva Pharmaceutical Industries will pay $10 million for the rights to Heptares’s small-molecule antagonists of a GPCR protein called CGRP for the treatment of migraines. Teva says the Heptares molecules will complement its TEV-48125, an anti-CGRP antibody.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X